Medical Foods for Inborn Errors of Metabolism Market Report 2025

The medical foods for inborn errors of metabolism market size has grown rapidly in recent years. It will grow from $3.08 billion in 2024 to $3.47 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to global health initiatives, increased recognition of nutritional therapies, precision medicine approaches, increasing incidence of metabolic disorders, and personalized digital nutrition platforms.

The medical foods for inborn errors of metabolism market size is expected to see rapid growth in the next few years. It will grow to $5.43 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to telehealth integration, rising demand for clean-label products, expanded newborn screening programs, patient-centric care models, and plant-based and sustainable formulations. Major trends in the forecast period include technological advancements in genetic testing, advancements in food processing technologies, innovations in ingredient technology, and technological advancements in food formulation.

The increasing prevalence of genetic (inherited) disorders is anticipated to drive the growth of the medical foods market for inborn errors of metabolism in the coming years. Genetic disorders are conditions caused entirely or partially by variations in the standard DNA sequence. Medical foods play a crucial role in providing specialized nutrition for infants with metabolic disorders, tailored to meet their unique metabolic needs, thus helping to prevent nutritional deficiencies and support their growth and overall well-being. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, reported that sickle cell disease (SCD) affects approximately 100,000 individuals in the United States, with over 90% of those impacted being non-Hispanic Black or African American, and an estimated 3%-9% being Hispanic or Latino. Consequently, the rise in genetic disorders is fueling the growth of the medical foods market for inborn errors of metabolism.

The increasing aging population is projected to boost the growth of the medical food market for inborn errors of metabolism in the coming years. An aging population refers to a demographic trend marked by a growing percentage of elderly individuals within a society. Medical food for inborn errors of metabolism caters to the nutritional needs and metabolic challenges faced by older adults with specific disorders. For instance, in January 2022, the Congressional Budget Office, a U.S.-based federal agency, estimated that the population eligible for Social Security payroll taxes and benefits would rise from 342 million in 2024 to 383 million by 2054. Additionally, the global population of individuals aged 60 and older is expected to double, reaching 2.1 billion by 2050. Thus, the rising aging population is driving the growth of the medical food market for inborn errors of metabolism.

Product innovation has become a prominent trend in the medical food market for inborn errors of metabolism. Leading companies in this sector are focusing on developing cutting-edge products to enhance their market presence. For instance, in October 2023, Galen Limited, a UK-based pharmaceutical firm, introduced PKU Easy Microtabs Plus as part of its Medical Nutrition line. This product is designed to aid in the dietary management of Phenylketonuria (PKU), a metabolic disorder. PKU Easy Microtabs Plus provides patients with a more convenient and precise way to control their phenylalanine levels through small, easy-to-swallow microtabs. This innovative formulation aims to improve the quality of life for individuals with PKU by facilitating better dose customization and ease of use.

Major companies in the medical food for inborn errors of metabolism market are also directing their efforts towards developing innovative metabolic products, such as solid-dose protein substitutes, to address dietary management needs and gain a competitive edge. A notable example is Galen Medical Nutrition, an Ireland-based company, which, in October 2022, introduced TYR EASY Tablets into the UK market. These unique solid-dose protein substitutes for tyrosinemia are provided in tablet form and cater to patients over the age of 8, offering more options for protein substitutes tailored to their daily requirements.

In July 2023, Pentec Health, a US-based provider of specialty infusion services and medical foods, acquired ZOIA Pharma for an undisclosed amount. Through this acquisition, Pentec Health aims to enhance its product portfolio by incorporating the PKU GOLIKE family of medical food products, specifically designed for the dietary management of phenylketonuria (PKU). The PKU GOLIKE range offers patients innovative options to effectively manage their protein intake. ZOIA Pharma is a US-based organization dedicated to developing medical food specifically for inborn errors of metabolism.

Major companies operating in the medical foods for inborn errors of metabolism market include Nestlé Health Science, Abbott Laboratories, Danone Nutricia, Vitaflo International Ltd., BioMarin Pharmaceutical Inc., Cambrooke Therapeutics Inc., Galen US Inc., Nutricia North America, Solace Nutrition LLC, Nutricia Advanced Medical Nutrition, Ajinomoto Cambrooke Inc., Primus Pharmaceuticals Inc., Applied Nutrition Corp., Metagenics Inc., PKU Perspectives Inc., Medtrition Inc., Nutricia Pty Ltd., Arla Foods Ingredients Group P/S, Aegle Nutrition LLC, Homestat Farm Ltd., Ketovie Nutrition, Formulaid, International Nutrition Inc., Phesgo Medical Foods, Immedica Pharma AB, Meiji Holdings Co. Ltd.

North America was the dominant region in the medical foods for inborn errors of metabolism market in 2024. The regions covered in the medical foods for inborn errors of metabolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical foods for inborn errors of metabolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Medical foods for inborn errors of metabolism encompass dietary supplements tailored for individuals with genetic conditions impacting metabolic functions. These products address specific nutritional needs in the management of these conditions. Key categories include amino acid formulations, glytactin with GMP amino acid-modified infant formula with iron, low-calcium/vitamin D-free infant formula with iron, low protein foods, and more. Amino acids, essential components found in living cells, are employed in medical foods for inborn errors of metabolism to offer alternative sources of crucial amino acids, bypassing those the individual's body struggles to metabolize effectively.

These medical foods cater to a range of disorders, including phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, methylmalonic acidemia, organic acidurias, propionic acidemia, isovaleric acidemia, disorders of leucine metabolism, glutaric acidemia type I, renal disease, and others. Tailored for various age groups such as infants, weaning, adolescents, and adults, these products are available in diverse forms such as powders, liquids, gels, and more. Distribution channels include retail pharmacies, hospital pharmacies, drug stores, online pharmacies, and other relevant outlets.

The medical foods for inborn errors of metabolism market research report is one of a series of new reports that provides medical foods for inborn errors of metabolism market statistics, including medical foods for inborn errors of metabolism industry global market size, regional shares, competitors with a medical foods for inborn errors of metabolism market share, detailed medical foods for inborn errors of metabolism market segments, medical foods for inborn errors of metabolism market trends and opportunities, and any further data you may need to thrive in the medical foods for inborn errors of metabolism industry. This medical foods for inborn errors of metabolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The medical food for inborn errors of the metabolism market consists of sales of galactose-free formulas, modified starches and carbohydrate supplements, and Vitamin pyridoxine (B6) supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.